These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 19842998)

  • 1. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.
    Albrecht S; Buerger E
    Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease.
    Schapira AH
    Neurology; 2009 Feb; 72(7 Suppl):S44-50. PubMed ID: 19221314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
    Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
    Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
    Clarke CE
    Mov Disord; 2008 Apr; 23(6):784-9. PubMed ID: 18175348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity.
    Izumi Y; Sawada H; Yamamoto N; Kume T; Katsuki H; Shimohama S; Akaike A
    Eur J Pharmacol; 2007 Feb; 557(2-3):132-40. PubMed ID: 17161393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotection and dopamine agonists.
    Schapira AH
    Neurology; 2002 Feb; 58(4 Suppl 1):S9-18. PubMed ID: 11909981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
    Olanow CW
    Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
    Verma R; Nehru B
    Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity.
    Imamura K; Takeshima T; Nakaso K; Ito S; Nakashima K
    Neurosci Lett; 2008 Aug; 440(2):97-102. PubMed ID: 18555604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.
    Relja M; Klepac N
    J Neurol Sci; 2006 Oct; 248(1-2):251-4. PubMed ID: 16797593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
    Costa A; Peppe A; Dell'Agnello G; Caltagirone C; Carlesimo GA
    Neuropsychologia; 2009 Apr; 47(5):1374-81. PubMed ID: 19428401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR: a therapeutic target in Parkinson's disease.
    Chaturvedi RK; Beal MF
    J Neurochem; 2008 Jul; 106(2):506-18. PubMed ID: 18384649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective therapy in Parkinson disease.
    Chen S; Le W
    Am J Ther; 2006; 13(5):445-57. PubMed ID: 16988541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current preclinical findings on substances against Parkinson's disease].
    Gerlach M; Riederer P
    Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.